drugset / Trial / NCT03493841

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

NCT03493841

Phase 1 Completed 20 enrolled Rebecca Spain
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a three-week crossover study that will compare how the body absorbs and tolerates two different forms of lipoic acid: R form and racemic form.

Timeline

Start
2018-06-08
Primary completion
2019-01-25
Completion
2019-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject alpha-lipoic acid Small molecule 600 mg Oral
Subject alpha-lipoic acid Small molecule 1200 mg Oral